Novel enzyme inhibitors for the treatment of aggressive forms of breast cancer

Breast cancer is the most common cancer in women. Some forms are very aggressive due to their invasive growth and the high frequency of metastases. Treatment is extremely difficult and costly, especially when highly specific antibodies are applied. Two enzymes play a major role in the development of tumors – HER2 and Brk. Enzyme inhibitors developed so far only inhibit HER2. The effectiveness is however limited since resistance has developed due to mutations in HER2. Novel substances are provided which selectively inhibit HER2 and/or Brk. The application of these substances allows addressing three important processes concurrently: the receptor mediated tumor growth, the inhibition of apoptosis, and metastasis.

Further information: PDF

ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20

Contact
Peter Lösler

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.